Regulation of pancreatic cancer therapy resistance by chemokines
Authors:
- 2 September 2022
- journal article
- research article
- Published by Elsevier in Seminars in Cancer Biology
- Vol. 86 (Pt 2) , 69-80
Abstract
No abstract availableKeywords
This publication has 165 references indexed in Scilit:
- Pancreatic Cancer Surgery in the New MillenniumAnnals of Surgery, 2011
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Overexpression of CXCL5 Is Associated With Poor Survival in Patients With Pancreatic CancerThe American Journal of Pathology, 2011
- CXCL12–CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapyBritish Journal of Cancer, 2010
- Gemcitabine remains the standard of care for pancreatic cancerNature Reviews Clinical Oncology, 2010
- High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinomaBritish Journal of Cancer, 2009
- Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell RecruitmentCancer Research, 2009
- Effects of Intratumoral Injection of CCL2 on Monocyte–Endothelial Cell Interactions in Mouse Pancreatic CancerMicrocirculation, 2007
- One Thousand Consecutive PancreaticoduodenectomiesAnnals of Surgery, 2006
- Dendritic cells delivered inside human carcinomas are sequestered by interleukin‐8International Journal of Cancer, 2005